Program
MC-1-50
Its studies are mostly in Lupus Erythematosus, Systemic · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, B-Cell, led by Chongqing Precision Biotech.
Furthest: phase 1, since Dec 12, 20233 company-led studies, 3 open or runningNext primary completion: Nov 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Precision Biotech | 33 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | Nov 1, 2027phase 1 · NCT06641024 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2023First study: phase 1 study in Lymphoma, B-CellFirst studyNCT06180174 · 24 planned · China
- Sep 27, 2024Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06641024 · 24 planned · China
- Mar 18, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06892145 · 12 planned · China
Ahead
- Nov 1, 2027Primary completion: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06641024
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06892145Lupus Erythematosus, Systemic · China | 1 | Recruiting | May 4, 2026 | 12 |
| NCT06641024Precursor Cell Lymphoblastic Leukemia-Lymphoma · China | 1 | Not yet recruiting | Nov 1, 2027 | 24 |
| NCT06180174Lymphoma, B-Cell · China | 1 | Recruiting | Dec 31, 2025 | 24 |
How it is read
Names in the registry
- “MC-1-50”, 3 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.